Laura Shawver on why she came back after an $88M windfall; MorphoSys taps Amgen vet as CCO
Laura Shawver didn’t quite understand cancer until she had it.
By that point, in 2006, she had already been making oncology drugs for over 15 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
